Aliskiren    (DrugBank: Aliskiren)

4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
66IgA腎症4
167マルファン症候群1
222一次性ネフローゼ症候群3
223一次性膜性増殖性糸球体腎炎1

66. IgA腎症 [臨床試験数:199,薬物数:214(DrugBank:57),標的遺伝子数:32,標的パスウェイ数:128
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 199 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01184599
(ClinicalTrials.gov)
June 201016/8/2010A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA NephropathyGlomerulonephritis, IGA;HypertensionDrug: aliskirenKagawa UniversityNULLRecruiting16 Years75 YearsBoth30Phase 4Japan
2NCT01129557
(ClinicalTrials.gov)
September 200921/5/2010Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseAldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney DiseaseProteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, MembranousDrug: Aliskiren;Drug: ValsartanColumbia UniversityNovartis PharmaceuticalsTerminated18 YearsN/AAll46Phase 4United States
3NCT00922311
(ClinicalTrials.gov)
July 200914/6/2009Aliskiren for Proteinuric IgAN Despite Angiotensin BlockadeAliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot StudyIgA NephropathyDrug: AliskirenThe University of Hong KongQueen Mary Hospital, Hong Kong;United Christian HospitalCompleted18 Years70 YearsBoth25Phase 4China
4NCT00870493
(ClinicalTrials.gov)
April 200926/3/2009Aliskiren for Immunoglobulin A (IgA) NephropathyThe Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over StudyIgA NephropathyDrug: Aliskiren;Drug: PlaceboChinese University of Hong KongNULLCompleted18 Years65 YearsBoth22Phase 3Hong Kong

167. マルファン症候群 [臨床試験数:19,薬物数:38(DrugBank:10),標的遺伝子数:10,標的パスウェイ数:49
Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 19 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01715207
(ClinicalTrials.gov)
June 201024/10/2012Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFSComparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With AtenololMarfan SyndromeDrug: Aliskiren;Drug: AtenololSamsung Medical CenterNULLCompleted14 Years55 YearsAll30Phase 3Korea, Republic of

222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 234 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04183101
(ClinicalTrials.gov)
October 1, 202014/11/2019Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyPhase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 GlomerulopathyC3 Glomerulopathy;Membranoproliferative Glomerulonephritis;Complement Abnormality;Dense Deposit Disease;C3 GlomerulonephritisDrug: Aliskiren;Drug: EnalaprilRegion SkaneNULLRecruiting6 YearsN/AAll30Phase 2Sweden
2NCT01093781
(ClinicalTrials.gov)
November 201024/3/2010Aliskiren in Patients With Idiopathic Membranous NephropathyA Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous NephropathyIdiopathic Membranous NephropathyDrug: AliskirenMayo ClinicNULLWithdrawn18 Years80 YearsBoth0N/AUnited States
3NCT01129557
(ClinicalTrials.gov)
September 200921/5/2010Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseAldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney DiseaseProteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, MembranousDrug: Aliskiren;Drug: ValsartanColumbia UniversityNovartis PharmaceuticalsTerminated18 YearsN/AAll46Phase 4United States

223. 一次性膜性増殖性糸球体腎炎 [臨床試験数:18,薬物数:14(DrugBank:7),標的遺伝子数:7,標的パスウェイ数:14
Searched query = "Primary membranoproliferative glomerulonephritis", "Dense deposit disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 18 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04183101
(ClinicalTrials.gov)
October 1, 202014/11/2019Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyPhase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 GlomerulopathyC3 Glomerulopathy;Membranoproliferative Glomerulonephritis;Complement Abnormality;Dense Deposit Disease;C3 GlomerulonephritisDrug: Aliskiren;Drug: EnalaprilRegion SkaneNULLRecruiting6 YearsN/AAll30Phase 2Sweden